vs
CareDx, Inc.（CDNA）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是CareDx, Inc.的1.8倍（$217.4M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs 1.4%，领先0.9%），CareDx, Inc.同比增速更快（39.0% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs 3.0%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
CDNA vs RPD — 直观对比
营收规模更大
RPD
是对方的1.8倍
$117.7M
营收增速更快
CDNA
高出38.5%
0.5%
净利率更高
CDNA
高出0.9%
1.4%
自由现金流更多
RPD
多$35.9M
$514.0K
两年增速更快
CDNA
近两年复合增速
3.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $217.4M |
| 净利润 | $2.8M | $3.1M |
| 毛利率 | — | 68.9% |
| 营业利润率 | 1.0% | 1.0% |
| 净利率 | 2.4% | 1.4% |
| 营收同比 | 39.0% | 0.5% |
| 净利润同比 | — | 44.1% |
| 每股收益（稀释后） | $0.05 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARPD
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $217.4M | ||
| Q3 25 | $100.1M | $218.0M | ||
| Q2 25 | $86.7M | $214.2M | ||
| Q1 25 | $84.7M | $210.3M | ||
| Q4 24 | $86.6M | $216.3M | ||
| Q3 24 | $82.9M | $214.7M | ||
| Q2 24 | $92.3M | $208.0M |
净利润CDNARPD
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $3.1M | ||
| Q3 25 | $1.7M | $9.8M | ||
| Q2 25 | $-8.6M | $8.3M | ||
| Q1 25 | $-10.4M | $2.1M | ||
| Q4 24 | $87.7M | $2.2M | ||
| Q3 24 | $-10.6M | $15.4M | ||
| Q2 24 | $-4.6M | $6.5M |
毛利率CDNARPD
| Q1 26 | — | — | ||
| Q4 25 | — | 68.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.6% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 70.7% |
营业利润率CDNARPD
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 1.0% | ||
| Q3 25 | -0.2% | 2.7% | ||
| Q2 25 | -12.8% | 1.6% | ||
| Q1 25 | -15.8% | -0.0% | ||
| Q4 24 | 97.5% | 3.4% | ||
| Q3 24 | -16.6% | 6.0% | ||
| Q2 24 | -7.9% | 2.5% |
净利率CDNARPD
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 1.4% | ||
| Q3 25 | 1.7% | 4.5% | ||
| Q2 25 | -9.9% | 3.9% | ||
| Q1 25 | -12.2% | 1.0% | ||
| Q4 24 | 101.3% | 1.0% | ||
| Q3 24 | -12.8% | 7.2% | ||
| Q2 24 | -5.0% | 3.1% |
每股收益（稀释后）CDNARPD
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.05 | ||
| Q3 25 | $0.03 | $0.15 | ||
| Q2 25 | $-0.16 | $0.13 | ||
| Q1 25 | $-0.19 | $0.03 | ||
| Q4 24 | $1.60 | $0.08 | ||
| Q3 24 | $-0.20 | $0.21 | ||
| Q2 24 | $-0.09 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $154.7M |
| 总资产 | $411.1M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARPD
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $474.7M | ||
| Q3 25 | $194.2M | $407.1M | ||
| Q2 25 | $186.3M | $511.7M | ||
| Q1 25 | $230.9M | $493.5M | ||
| Q4 24 | $260.7M | $521.7M | ||
| Q3 24 | $240.9M | $443.7M | ||
| Q2 24 | $228.9M | $442.6M |
总债务CDNARPD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARPD
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $154.7M | ||
| Q3 25 | $311.1M | $127.2M | ||
| Q2 25 | $327.4M | $90.4M | ||
| Q1 25 | $379.3M | $52.7M | ||
| Q4 24 | $378.4M | $17.7M | ||
| Q3 24 | $273.2M | $-5.1M | ||
| Q2 24 | $264.7M | $-52.6M |
总资产CDNARPD
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.7B | ||
| Q3 25 | $432.3M | $1.7B | ||
| Q2 25 | $444.3M | $1.6B | ||
| Q1 25 | $489.6M | $1.6B | ||
| Q4 24 | $491.1M | $1.7B | ||
| Q3 24 | $477.0M | $1.6B | ||
| Q2 24 | $466.8M | $1.5B |
负债/权益比CDNARPD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $36.4M |
| 自由现金流率自由现金流/营收 | 0.4% | 16.8% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 1.54× | 12.01× |
| 过去12个月自由现金流最近4个季度 | — | $146.2M |
8季度趋势，按日历期对齐
经营现金流CDNARPD
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $37.6M | ||
| Q3 25 | $37.4M | $39.0M | ||
| Q2 25 | $9.9M | $47.5M | ||
| Q1 25 | $-26.6M | $29.8M | ||
| Q4 24 | $21.9M | $63.8M | ||
| Q3 24 | $12.5M | $44.0M | ||
| Q2 24 | $18.9M | $32.9M |
自由现金流CDNARPD
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $36.4M | ||
| Q3 25 | — | $34.8M | ||
| Q2 25 | — | $46.6M | ||
| Q1 25 | — | $28.4M | ||
| Q4 24 | — | $62.6M | ||
| Q3 24 | — | $42.6M | ||
| Q2 24 | — | $32.6M |
自由现金流率CDNARPD
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 16.0% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 13.5% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | — | 15.7% |
资本支出强度CDNARPD
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.1% |
现金转化率CDNARPD
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | 12.01× | ||
| Q3 25 | 22.30× | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | 0.25× | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
